Rapport Therapeutics, Inc. Increase (Decrease) in Other Operating Assets
Rapport Therapeutics, Inc. (RAPP) reported Increase (Decrease) in Other Operating Assets of -$346.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingAssets · last filed 2026-08-05
- Rapport Therapeutics, Inc. increase (decrease) in other operating assets for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Rapport Therapeutics, Inc. increase (decrease) in other operating assets for the quarter ending 2026-03-31 was -$346.00K, a 778.43% decline year-over-year.
- Rapport Therapeutics, Inc. increase (decrease) in other operating assets for the quarter ending 2025-12-31 was -$119.00K.
- Rapport Therapeutics, Inc. increase (decrease) in other operating assets for the quarter ending 2025-09-30 was $362.00K.
- Rapport Therapeutics, Inc. increase (decrease) in other operating assets for fiscal 2025 was $791.00K.
- Rapport Therapeutics, Inc. increase (decrease) in other operating assets for fiscal 2024 was -$83.00K, a 134.58% decline from fiscal 2023.
- Rapport Therapeutics, Inc. increase (decrease) in other operating assets for fiscal 2023 was $240.00K.
| Period end | Increase (Decrease) in Other Operating Assets 3 month | Increase (Decrease) in Other Operating Assets 6 month | Increase (Decrease) in Other Operating Assets 9 month | Increase (Decrease) in Other Operating Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$346.00K 10-Q · filed 2026-08-05 | -$465.00K derived: sum of 3 quarters · filed 2026-08-05 | -$103.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$346.00K 10-Q · filed 2026-05-07 | -$465.00K derived: sum of 2 quarters · filed 2026-05-07 | -$103.00K derived: sum of 3 quarters · filed 2026-05-07 | $394.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$119.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $243.00K derived: sum of 2 quarters · filed 2026-03-10 | $740.00K derived: sum of 3 quarters · filed 2026-08-05 | $791.00K 10-K · filed 2026-03-10 |
| 2025-09-30 | $362.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $859.00K derived: sum of 2 quarters · filed 2026-08-05 | $910.00K 10-Q · filed 2025-11-06 | $878.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $497.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $548.00K 10-Q · filed 2026-08-05 | $516.00K derived: sum of 3 quarters · filed 2026-08-05 | $516.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $51.00K 10-Q · filed 2026-05-07 | $19.00K derived: sum of 2 quarters · filed 2026-05-07 | $19.00K derived: sum of 3 quarters · filed 2026-05-07 | -$5.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$32.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$32.00K derived: sum of 2 quarters · filed 2026-03-10 | -$56.00K derived: sum of 3 quarters · filed 2026-03-10 | -$83.00K 10-K · filed 2026-03-10 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$24.00K derived: sum of 2 quarters · filed 2025-11-06 | -$51.00K 10-Q · filed 2025-11-06 | $64.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$24.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$51.00K 10-Q · filed 2025-08-07 | $64.00K derived: sum of 3 quarters · filed 2025-08-07 | $40.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$27.00K 10-Q · filed 2025-05-08 | $88.00K derived: sum of 2 quarters · filed 2025-05-08 | $64.00K derived: sum of 3 quarters · filed 2025-05-08 | |
| 2023-12-31 | $115.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $91.00K derived: sum of 2 quarters · filed 2025-03-11 | $240.00K 10-K · filed 2025-03-11 | |
| 2023-09-30 | -$24.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $125.00K 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $149.00K 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |